suMMARY To assess the relation of hyperaldosteronism and potassium depletion to the intensity of diuretic therapy we have measured plasma aldosterone by radioimmunoassay and total exchangeable potassium by radioisotope dilution in 24 patients when they were stable at the end of their preparation for cardiac operation.
The fluid retention which is characteristic of chronic congestive heart failure arises from a disturbance of the homeostatic control of body sodium content (Merrill, 1946) , mediated in part by the reninangiotensin-aldosterone system which produces sodium retention in the distal renal tubule at the expense of loss of potassium and hydrogen ions. Until recently the part played by aldosterone has been difficult to define, partly because of technical factors as pointed out by Nicholls et al. (1974) and partly because of the paradoxical effect of diuretic therapy, which in the early stages of treatment of congestive failure reduces the activity of the reninangiotensin-aldosterone system (Laragh, 1962; Genest et al., 1968; Nicholls et al., 1974) , in contrast to the stimulation found with diuretics in normal subjects and in patients with hypertension (Laragh et al., 1972) . There is also a suggestion that the activity of the renin-angiotensin-aldosterone system is increased in heart failure as part of the general increase in sympathetic activity under these circumstances (Brod, 1972; Davis, 1974) . AldosterReceived for publication 15lJanuary 1979 one antagonists are often recommended in treatment to prevent both sodium retention and potassium loss; they may be particularly useful for chronic treatnent in the dried-out state, as Nicholls et al. (1974) have shown that hyperaldosteronism is a major feature in patients approaching dry weight on continued diuretic treatment.
Potassium depletion shown by a reduction in total exchangeable potassium is a major feature of patients with severe heart disease on diuretic treatment (White et al., 1969) and has been thought to contribute to the risks of surgical correction (Lockey et al., 1966) . However, more recent studies of total body potassium (Davidson et al., 1976; Lawson et al., 1976 ) measuring the natural radioisotope (40K) in a total body counter suggest that tissue potassium is only slightly depleted in relation to body size. The reduction in total exchangeable potassium may be, in the main, an indication of a loss of lean body mass as part of wasting which may be occult (Walesby et al., 1978) or evident in the extreme as 'cardiac cachexia', but local critical be excluded (Hamer, 1977) . The plasma potassium seems to be part of a labile component of the body potassium which varies without relation to total body stores (Croxson et al., 1972; Nagant de Deuxchaisnes and Mach, 1974; Nicholls et al., 1976) and cannot be used to predict potassium depletion. Plasma potassium may be relatively easily maintained by dietary supplements or aldosterone antagonists with relatively little effect on tissue potassium (White, 1970; Croxson et al., 1972; Davidson and Gillebrand, 1973; Kremer et al., 1977) . It is important to maintain a normal plasma potassium in patients being treated with digitalis as the tendency of digitalis to produce arrhythmias is potentiated by hypokalaemia (Naylor, 1975; Steiness and Olesen, 1976) .
Aldosterone antagonists may be more effective than dietary supplements of potassium in the longterm correction of tissue potassium losses (Croxson et al., 1972; Davidson and Gillebrand, 1973; Kremer et al., 1977) , perhaps on the basis of correcting cellular magnesium depletion Jacob, 1972, 1978; Dyckner and Wester, 1978) . With the possibility of the need for treatment with aldosterone antagonists in mind, the availability of a practicable and sensitive radioimmunoassay for plasma aldosterone led us to investigate the aldosterone and electrolyte status of our patients awaiting cardiac surgery.
Methods
We studied 24 patients (10 men and 14 women) mostly with valve disease (Table 1) being prepared in hospital for surgical treatment. The patients agreed to take part in the study after a full explanation of the detailed procedure and assurance that their operation would not be delayed or otherwise affected by the study. All were in a stable state after optimal treatment (Table 2) to reduce oedema and pulmonary congestion, as judged by constant body weight, and were studied in the few weeks between admission to hospital and operation; 2 patients (cases 22 and 24) had slight detectable residual oedema. Ethical considerations forbade any change in diuretic treatment or in general ward management; all patients received normal ward diet with 'no added salt' at the table and unlimited fluid intake. In all but 4 patients (cases 4, 7, 9, and 12) diuretic therapy was thought necessary and was sometimes intensive (Table 2) .
We attempted to maintain normal plasma potassium concentrations with potassium supplements (Slow K) or amiloride where necessary.
Total exchangeable potassium and sodium were estimated simultaneously with 43K and 24Na as suggested by Davies and Robertson (1973) , but injecting 100 ,uCi 43K and 20 , uCi Table 4 ) the 2 values for total exchangeable potassium differed by more than 15 per cent of the mean, and these patients were excluded from the regression analysis. The excretion of 43K and 24Na in the first 24 hours was assumed to be 3 per cent (Oleson, 1967; White et al., 1969 Total body water was estimated as 'cation space', the volume occupied by the sum of total exchangeable sodium (TENa) (representing mainly extracellular fluid) and total exchangeable potassium (TEK) (representing mainly cell water), dividing total cation (TENa + TEK) by extracellular (i.e. plasma) total cation concentration (Na + K) expressed in terms of extracellular water and assuming osmotic equilibrium between cells and extracellular fluid (Oleson, 1967) . We measured extracellular fluid volume as sulphate space, using the method of Savoie and Jungers (1965) as outlined by White et al. (1969) , modified by using a new xylene-based liquid scintillator (NE 260, Nuclear Enterprises) to which plasma can be added directly without protein precipitation. Plasma was stored for 7 days in a deep freeze to ensure complete decay of 24Na and 43K before counting and 35S was counted in a Beckman automatic liquid scintillation counter. The observed sulphate space was corrected for plasma water content, Donnan equilibrium, and the entry of radiosulphate into red cells by multiplying by a factor of 0 93, differing from the value of 0-87 used by White et al. (1969) as plasma proteins are not now removed before measurement.
Extracellular sodium was calculated by multiplying the corrected sulphate space by the overall extracellular fluid sodium concentration, estimated as plasma sodium multiplied by 1 02 (White et al., 1969) . The residual sodium, that is sodium in cells or to a small extent elsewhere not exchanging with the extracellular fluid (Leaf, 1974) , was calculated as the difference between total exchangeable sodium and extracellular sodium.
Plasma aldosterone was determined by the radioimmunoassay procedure described by Jowett et al. (1973) .1,23H-aldosterone (50 Ci/mmol) was obtained from the Radiochemical Centre, Amersham, and from New England Nuclear. D-aldosterone was obtained from Koch-Light Laboratories and chromatography carried out using the Bush B5 system on Whatman's SG81 silica gel-impregnated paper. Antibody to aldosterone-3-carboxymethoxime conjugated to bovine serum albumin was donated by Dr J. D. H. Slater (Middlesex Hospital) and used at a final dilution of 1:600. Standard curves were set from 0 to 160 pg/ml aldosterone.
Aldosterone assays were carried out in duplicate and the duplicate variation was between 1 and 2 per cent. Each sample was assayed on three separate occasions and the interassay variation was 10 per cent. A water blank was included with each batch of samples being assayed; blank values were always less than 6 pg/ml. Aldosterone levels were measured in 8 normal volunteers between 12 noon and 2 pm, the blood being taken with the subject recumbent after at least 4 hours in the erect posture.
In 15 patients cardiac catheterisation was carried out as part of their preoperative assessment (Table  3) .
Results
The detailed findings, including plasma electrolyte values, are listed in Table 4 278, 302, 291, 272, 413, 563, 161, and 250 pmol/l (100, 109, 105, showed a relation to the plasma aldosterone expressed logarithmically.
There was a poor correlation between log1o aldosterone concentration and plasma potassium (r=0-40), but log1o aldosterone concentration correlated negatively with plasma sodium (r=-0-5, P<0 01).
Various methods for the correction of total exchangeable potassium (TEK) for body size made (Castro et al., 1974 ).
The levels in our patients (Tables 2, 3 , 4, and 5) fall into 3 groups: 13 patients with normal or slightly raised levels up to 833 pmol/l (300 ng/l), a middle range (6 patients) with values between 833 and 2775 pmol/l (300 and 1000 ng/l), and a high range above 2775 pmol/l (1000 ng/l) (5 patients). In view of the wide variation in plasma aldosterone concentrations, regression analyses were carried out to determine whether any ofour other measurements differed by more than 15 per cent of the mean and they are little difference and a similar relation was found between log1o aldosterone concentration and unmodified total exchangeable potassium (r= -0-63, P < 0 01), total exchangeable potassium/metre height (r= -.064, P <0O01) (Fig. 1) , and total exchangeable potassium/kg body weight (r= -059, P <0 01). There was no correlation between total exchangeable sodium and plasma aldosterone concentration.
There was a negative relation between log1o plasma aldosterone concentration and sulphate space (r= -.029) (Fig. 2) A highly significant correlation was found in patients on frusemide between logl0 frusemide and aldosterone concentration (r =077, P < 0-001) (Fig.  3) . The use of log frusemide dose necessarily excludes patients not on frusemide from this correlation. The correlation with logl0 amiloride dose did not achieve significance (r=0 51, P < 0.1).
Discussion

ROLE OF ALDOSTERONE IN CONGESTIVE HEART FAILURE
The part played by aldosterone in the different stages of congestive heart failure in relation to the response to diuretic therapy has been clarified with the measurement of plasma aldosterone by Nicholls et al. (1974) , and the findings can be interpreted in relation to the two major stimuli to renin release; a reduction in the effective arterial volume and a fall in the sodium load reaching the distal tubule (Vander, 1967) . At the onset of heart failure and in the untreated situation a moderate increase in plasma aldosterone is expected as part of the increase in sympathetic activity (Brod, 1972) and the primary stimulus to fluid retention (Davis, 1974 ) from a fall in effective arterial volume or a reduced sodium load in the distal tubule after enhanced reabsorption proximally.
During diuresis plasma aldosterone is suppressed to very low levels. The attribution of this response to a reduction in the initial stimulus as cardiovascular performance improves seems unlikely in view of the lack of haemodynamic improvement noted after diuretic therapy by Stampfer et al. (1968) . The dramatic increase in sodium load to the distal tubule during diuresis seems to outweigh the effect of a fall in effective arterial volume at this stage in the treatment of heart failure. As the patient approaches dry weight plasma aldosterone rises again. It may be that continued diuretic treatment after loss of oedema further reduces effective circulating arterial volume, and the sodium load reaching the distal tubule will be less than in the diuretic phase. It has been suggested that reduced catabolism of aldosterone from impaired hepatic function plays a part in producing the high plasma aldosterone concentration in congestive heart failure (Yates et al., 1958; Tait et al., 1965; Genest et al., 1968) , but Nicholls et al. (1974) found that plasma renin activity changed in parallel with the plasma aldosterone concentration, suggesting that the 'renin-angiotensin-aldosterone' system continues to operate.
RADIOISOTOPE METHODS Oleson and Valentin (1973) confirmed the general validity of the radioisotope dilution method for total exchangeable potassium in the investigation of patients with treated heart failure. The apparent discrepancy with measurements of total body potassium from natural 40K in a whole body counter is probably related to differences in interpretation (Hamer, 1977) . The finding of near normal total body potassium in relation to current weight (Davidson et al., 1976; Lawson et al., 1976 ) is in keeping with the suggestion of Nagant de Deuxchaisnes et al. (1961) and Nagent de Deuxchaisnes and Mach (1974) that the loss of potassium seen with total exchangeable potassium measurements is a 'pseudodepletion' caused by loss of lean body mass. The main bulk of body potassium is contained in skeletal muscle. Because of the variable effects of fluid retention, obesity, and loss of lean tissue from cardiac cachexia the lean body mass bears no fixed relation to body weight in treated severe heart disease (Rich and Wright, 1978) . Our assessments of depleted total exchangeable potassium are based on estimates of normal body size derived from height and are consistent with loss of lean body mass (White et al., 1969) .
The suggestion of Oleson and Valetin (1973) that sodium did not enter cells to replace lost potassium in treated heart failure may be the result of technical problems related to their use of 82Br, an analogue of the chloride (Cl) ion as a marker of extracellular fluid volume (Hamer, 1977) . The sulphate ion used here has advantages for the measurement of extracellular fluid volume in that it does not penetrate cells to a significant extent, but measurement is more complicated as back-extrapolation of the data to the time of injection is needed to allow for renal excretion of sulphate (Savoie and Jungers, 1965) . The evidence that many patients have larger total exchangeable sodium than accounted for by sodium in the extracellular fluid (Fig. 4) indicates some entry of sodium into the cells consistent with a fall in intracellular potassium concentration, the 'true depletion' of Nagant de Deuxchaisnes et al. (1961) and Nagent de Deuxchaisnes and Mach (1974) as shown for skeletal muscle in primary hyperaldosteronism by Milne et al. (1967) , and in Bartter's syndrome by Delaporte et al. (1978) . The absence of such findings in our previous study (White et al., 1969) on similar patients may relate to the difficulty of measurement of small changes when 'pseudo-depletion' is the dominant factor. Though muscle wasting from the process of malnutrition (Walesby et al., 1978 ) that leads to 'cardiac cachexia' seems to play a major role in reducing total exchangeable potassium from loss of lean body mass (i.e. a 'pseudodepletion'), some 'true depletion' producing a reduction of intracellular potassium concentration is difficult to exclude and could be of critical importance in the myocardium, changing the membrane potential to produce fatal ventricular arrhythmias as stressed by Lockey et al. (1966) , though Oleson and Valentin (1973) failed to confirm any increased risk of death from arrhythmias with reduced total exchangeable potassium in their patients. Myocardial biopsies at operation show reduced cell potassium concentration (Schimert et al., 1966) , but Taggart and Slater (1970) have shown that similar changes may occur during operation, so they may not represent the preoperative state, and Ward and Cameron (1978) have shown in animals that the myocardium is relatively protected against potassium depletion.
The state of many of our patients on continued diuretic treatment after the loss of most of their oedema corresponds to the dried-out stage described by Nicholls et al. (1974) in which hyperaldosteronism is frequent.
Care was taken to ensure that the patients had reached a steady state, as far as the diuretic regimen was concerned, as indicated by a constant body weight and the patients were studied after several hours in the sitting position to minimise the effects of posture on plasma aldosterone. The very high concentrations found in some patients were in and beyond the range (up to 2 nmol/l =720 ng/l) found by Nicholls et al. (1974) after relatively short periods of diuretic treatment in patients approaching dry weight, and are far beyond the range expected from postural variations. The 'no added salt' diet may have acted as a stimulus to renin secretion, producing a secondary rise in plasma aldosterone concentration. Though they were generally free from oedema our patients did not show extreme sodium depletion. There was also evidence from the tendency to a raised total exchangeable sodium in the men studied, from the increased cation space, and from the absence of any general fall in extracellular fluid volume (sulphate space), of persisting expansion of the extracellular fluid. Nevertheless, it is difficult to exclude a reduction in effective arterial volume provoking secretion of renin and a consequent hyperaldosteronism; such a change is suggested by the higher plasma aldosterone levels with reduced sulphate space and may be obscured in measurements of total extracellular fluid volume by a persisting increase in the volume of the venous compartment and the pulmonary circulation. The absence of any correlation between plasma aldosterone and cardiac output may indicate that blood flow is not the critical factor, but is more likely to reflect the different conditions of study.
Previous studies (White, 1970) have shown that potassium supplements have only a partial effect in correcting the reduced total exchangeable potassium in keeping with the description of hypokalaemia as a simple potassium 'deficiency' by Nagant de Deuxchaisnes et al. (1961) and Nagant de Deuxchaisnes and Mach (1974) , suggesting that treatment directed to reversing hyperaldosteronism might be a more useful approach to correcting potassium losses in the present situation. Relatively short-term treatment with amiloride has only a minor effect on tissue potassium (Croxson et al., 1972; Davidson and Gillebrand, 1973; Kremer et al., 1977) and attempts to correct potassium depletion caused by loss of lean body mass may be inappropriate, short of haemodynamic correction. We are hopeful that more prolonged treatment or other approaches such as reducing cardiac load by chronic vasodilator therapy (Chatterjee et al., 1976) , or a metabolic approach by correcting magnesium depletion (Dyckner and Wester, 1978; Lim and Jacob, 1978) , or the insulin and glucose regimen (Majid et al., 1972) may restore potassium to the cells effectively; further study is clearly necessary to determine the best approach to management of these severely affected patients.
INTERPRETATION OF PRESENT FINDINGS
We were concerned to assess the aldosterone situation in our patients with treated heart disease in relation to their preparation for operation, and we did not think it ethically justifiable to modify the conditions of treatment or to defer the patients' operations for the study. We are forced to argue the sequence of events from the results in individual patients with widely differing degrees of impairment (Table 1 ). In view of the fundamental similarity of the disturbed physiology leading to congestive heart failure, and as no clear separation of high and low plasma aldosterone levels was evident in our results we used regression analysis to determine the relations between the status or treatment of our patients and the biochemical measurements.
Patients on spironolactone were excluded to avoid possible interference with the aldosterone assay by metabolites but we were able to maintain normal plasma potassium levels with oral potassium supplements or amiloride where necessary in our patients. It seems unlikely that potassium administration played a part in provoking aldosterone secretion in our patients. The effect described by Laragh and Stoerk (1955) seems to be mediated by a direct action on the adrenal cortex, and the tendency to cellular potassium depletion in our patients might have the reverse effect, as suggested by Brunner et al. (1970) . Plasma aldosterone (pmol /1) (log scale) Fig. 2 Relation between plasma aldosterone concentration (log scale) and extracellular fluid volume measured as sulphate space. The negative correlation (r= -0 29) which does not achieve statistical significance suggests that hyperaldosteronism is associated with reduced extracellular fluid volume.
A positive feedback effect of aldosterone antagonism leading to further aldosterone secretion as reported in Conn's syndrome (Kremer et al., 1977) and in heart failure (Nicholls et al., 1976) (1974) concluded from a study of leucocyte electrolytes in cardiac and non-cardiac patients receiving diuretics that the heart disease rather than its treatment was responsible for the potassium depletion in cardiac patients, but their results are obscured by an apparent failure to consider the effects of digitalis glycosides which will also tend to deplete the leucocyte potassium concentration and may account for the difference between the 2 groups of patients (Astrup, 1974) . We show here a clear relation between intensive diuretic therapy, hyperaldosteronism, and loss ofbody potassium (measured as total exchangeable potassium).
It may be that in severely affected patients, intensive diuretic treatment serves only to remove troublesome systemic and pulmonary oedema, reducing pulmonary vascular pressures and producing a fall rather than a rise in cardiac output in spite of clinical improvement from loss of congestion as described by Stampfer et al. (1968) . We conclude that though the clinical condition of patients is improved by diuretic therapy, the persisting or accentuated reduction in effective arterial volume 2800 3400 4000 4600 Total exchangeable Na' (mmol) Fig. 4 leads to severe hyperaldosteronism which produces potassium depletion and may be complicated by loss of lean body mass and cardiac cachexia. In addition there is risk of a fall in intracellular potassium concentration which can precipitate fatal ventricular arrhythmias (Dreifus et al., 1974) . It may be that less intensive diuretic therapy would avoid the provocation of hyperaldosteronism at the expense of some residual oedema, but the relative success of operating on dried-out patients makes us hestitant to abandon this policy.
Whatever the mechanisms, whether arrhythmic or through wasting of lean tissue (Walesby et al., 1978) , it is possible that hyperaldosteronism and potassium depletion may contribute to the mortality of surgical treatment such as valve replacement. If operation is feasible, our surgical colleague suggests that it should be considered before hyperaldosteronism occurs, as soon as intensive diuretic treatment becomes necessary to prevent troublesome symptoms of congestion (G. Rees, 1977, personal communication) .
A preliminary account of this work was presented to the joint meeting of the British Cardiac Society and the Swedish Society of Cardiology in 1975, and appears in abstract in the British Heart Journal, 35, 534P; the findings are reviewed by Hamer (1977) . 
